ADVANCIS TO CONDUCT ADDITIONAL ADULT AMOXICILLIN TRIAL

Advancis Pharmaceutical announced that it will conduct a new Phase III trial for its Amoxicillin PULSYS product candidate in adults and adolescents with pharyngitis/tonsillitis due to Group A strep infections. Enrollment in the clinical trial is expected to begin in the fourth quarter of 2005.

Advancis' pivotal trial is expected to be designed as a 600-patient, double-blind, double-dummy, non-inferiority trial. The company anticipates comparing its Amoxicillin PULSYS dosage form, delivered in a once-daily, 775 mg tablet for a period of 10 days, to 250 mg of penicillin dosed four times daily.